Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974428802> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W1974428802 endingPage "310" @default.
- W1974428802 startingPage "309" @default.
- W1974428802 abstract "No standard treatment exists for patients with platinum-refractory urothelial cancer. Taxanes and vinflunine are commonly used, but response is less than 20% with no survival benefit. In this phase 2 study, we assessed efficacy and tolerability of nanoparticle albumin-bound (nab) paclitaxel in platinum-refractory urothelial cancer.We did an open-label, single-group, two-stage study at five centres in Canada. We enrolled patients aged at least 18 years with histologically confirmed, locally advanced, or metastatic measurable urothelial cancer, with documented progression on or within 12 months of treatment with one previous platinum-containing regimen. Patients received nab-paclitaxel at 260 mg/m2 intravenously every 3 weeks. Treatment continued until disease progression or occurrence of unacceptable toxic effects. The primary endpoint was objective tumour response, defined by a complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (version 1.0) criteria. Tumour response and safety were assessed in all patients who received at least one cycle of nab-paclitaxel. This study is registered with ClinicalTrials.gov, number NCT00683059.We enrolled 48 patients between Oct 16, 2008, and June 23, 2010. Patients received a median of six cycles (range one to 15). 47 patients were evaluable; one (2·1%) had a CR and 12 (25·5%) had PRs, resulting in an overall response of 27·7% (95% CI 17·3–44·4). The most frequently recorded adverse events of any grade were fatigue (38 of 48; 79%), pain (37 of 48; 77%), alopecia (34 of 48; 71%), and neuropathy (30 of 48; 77%). The most frequently recorded adverse events of grade 3 or higher were pain (11 of 48; 23%), fatigue (five of 48; 23%), hypertension (three of 48; 6%), neuropathy (three of 48, 6%), and joint stiffness or pain (two of 48; 4%).Nab-paclitaxel was well tolerated in this population of patients with pretreated advanced urothelial cancer with an encouraging tumour response. These results warrant further study of nab-paclitaxel in second-line treatment of urothelial cancer.Abraxis Bioscience, Celgene." @default.
- W1974428802 created "2016-06-24" @default.
- W1974428802 creator A5035822430 @default.
- W1974428802 date "2007-09-01" @default.
- W1974428802 modified "2023-09-25" @default.
- W1974428802 title "4537 POSTER Late recurrences (LR) in germ cell testicular tumours (GCTT): a population-based experience over 23 years" @default.
- W1974428802 doi "https://doi.org/10.1016/s1359-6349(07)71168-0" @default.
- W1974428802 hasPublicationYear "2007" @default.
- W1974428802 type Work @default.
- W1974428802 sameAs 1974428802 @default.
- W1974428802 citedByCount "1" @default.
- W1974428802 countsByYear W19744288022013 @default.
- W1974428802 crossrefType "journal-article" @default.
- W1974428802 hasAuthorship W1974428802A5035822430 @default.
- W1974428802 hasConcept C121332964 @default.
- W1974428802 hasConcept C126322002 @default.
- W1974428802 hasConcept C141071460 @default.
- W1974428802 hasConcept C142424586 @default.
- W1974428802 hasConcept C197934379 @default.
- W1974428802 hasConcept C203092338 @default.
- W1974428802 hasConcept C2776694085 @default.
- W1974428802 hasConcept C2777292972 @default.
- W1974428802 hasConcept C2778375690 @default.
- W1974428802 hasConcept C2778822529 @default.
- W1974428802 hasConcept C2779984678 @default.
- W1974428802 hasConcept C2780739268 @default.
- W1974428802 hasConcept C2781413609 @default.
- W1974428802 hasConcept C2908647359 @default.
- W1974428802 hasConcept C535046627 @default.
- W1974428802 hasConcept C71924100 @default.
- W1974428802 hasConcept C87355193 @default.
- W1974428802 hasConcept C90924648 @default.
- W1974428802 hasConcept C99454951 @default.
- W1974428802 hasConceptScore W1974428802C121332964 @default.
- W1974428802 hasConceptScore W1974428802C126322002 @default.
- W1974428802 hasConceptScore W1974428802C141071460 @default.
- W1974428802 hasConceptScore W1974428802C142424586 @default.
- W1974428802 hasConceptScore W1974428802C197934379 @default.
- W1974428802 hasConceptScore W1974428802C203092338 @default.
- W1974428802 hasConceptScore W1974428802C2776694085 @default.
- W1974428802 hasConceptScore W1974428802C2777292972 @default.
- W1974428802 hasConceptScore W1974428802C2778375690 @default.
- W1974428802 hasConceptScore W1974428802C2778822529 @default.
- W1974428802 hasConceptScore W1974428802C2779984678 @default.
- W1974428802 hasConceptScore W1974428802C2780739268 @default.
- W1974428802 hasConceptScore W1974428802C2781413609 @default.
- W1974428802 hasConceptScore W1974428802C2908647359 @default.
- W1974428802 hasConceptScore W1974428802C535046627 @default.
- W1974428802 hasConceptScore W1974428802C71924100 @default.
- W1974428802 hasConceptScore W1974428802C87355193 @default.
- W1974428802 hasConceptScore W1974428802C90924648 @default.
- W1974428802 hasConceptScore W1974428802C99454951 @default.
- W1974428802 hasIssue "4" @default.
- W1974428802 hasLocation W19744288021 @default.
- W1974428802 hasOpenAccess W1974428802 @default.
- W1974428802 hasPrimaryLocation W19744288021 @default.
- W1974428802 hasRelatedWork W1991064094 @default.
- W1974428802 hasRelatedWork W2023989228 @default.
- W1974428802 hasRelatedWork W2040305814 @default.
- W1974428802 hasRelatedWork W2351476339 @default.
- W1974428802 hasRelatedWork W2436187249 @default.
- W1974428802 hasRelatedWork W2889701300 @default.
- W1974428802 hasRelatedWork W2910623846 @default.
- W1974428802 hasRelatedWork W3197516152 @default.
- W1974428802 hasRelatedWork W4205849946 @default.
- W1974428802 hasRelatedWork W4206543414 @default.
- W1974428802 hasVolume "5" @default.
- W1974428802 isParatext "false" @default.
- W1974428802 isRetracted "false" @default.
- W1974428802 magId "1974428802" @default.
- W1974428802 workType "article" @default.